CN1988902A - 含有类黄酮和生育三烯酚的功能性食品及其方法 - Google Patents
含有类黄酮和生育三烯酚的功能性食品及其方法 Download PDFInfo
- Publication number
- CN1988902A CN1988902A CNA2005800254064A CN200580025406A CN1988902A CN 1988902 A CN1988902 A CN 1988902A CN A2005800254064 A CNA2005800254064 A CN A2005800254064A CN 200580025406 A CN200580025406 A CN 200580025406A CN 1988902 A CN1988902 A CN 1988902A
- Authority
- CN
- China
- Prior art keywords
- functional food
- reduce
- administration
- tocotrienol
- make
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 144
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 64
- 150000002215 flavonoids Chemical class 0.000 title claims abstract description 64
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 64
- 229930003802 tocotrienol Natural products 0.000 title claims abstract description 59
- 239000011731 tocotrienol Substances 0.000 title claims abstract description 59
- 235000019148 tocotrienols Nutrition 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims description 27
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 title abstract 3
- 229940068778 tocotrienols Drugs 0.000 title abstract 3
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 22
- 239000013543 active substance Substances 0.000 claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 13
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims abstract description 10
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims abstract description 10
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 6
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims abstract description 6
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 6
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 6
- 229960001587 hesperetin Drugs 0.000 claims abstract description 6
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 6
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000007625 naringenin Nutrition 0.000 claims abstract description 6
- 229940117954 naringenin Drugs 0.000 claims abstract description 6
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims abstract description 5
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940064063 alpha tocotrienol Drugs 0.000 claims abstract description 5
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims abstract description 5
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims abstract description 5
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims abstract description 5
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims abstract description 5
- 235000019145 α-tocotrienol Nutrition 0.000 claims abstract description 5
- 239000011730 α-tocotrienol Substances 0.000 claims abstract description 5
- 235000019150 γ-tocotrienol Nutrition 0.000 claims abstract description 5
- 239000011722 γ-tocotrienol Substances 0.000 claims abstract description 5
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims abstract description 5
- 235000019144 δ-tocotrienol Nutrition 0.000 claims abstract description 5
- 239000011729 δ-tocotrienol Substances 0.000 claims abstract description 5
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims abstract description 5
- 229940112822 chewing gum Drugs 0.000 claims abstract description 3
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 56
- 235000020971 citrus fruits Nutrition 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 23
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 21
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 6
- 235000012467 brownies Nutrition 0.000 claims description 5
- 235000015243 ice cream Nutrition 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 241001047198 Scomberomorus semifasciatus Species 0.000 claims description 4
- 235000019219 chocolate Nutrition 0.000 claims description 4
- 235000014510 cooky Nutrition 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 4
- 235000020166 milkshake Nutrition 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 235000008603 tangeritin Nutrition 0.000 claims description 4
- 244000183685 Citrus aurantium Species 0.000 claims description 3
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 3
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims description 3
- 235000016646 Citrus taiwanica Nutrition 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- 235000013310 margarine Nutrition 0.000 claims description 3
- 239000003264 margarine Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims description 2
- 235000009392 Vitis Nutrition 0.000 claims description 2
- 241000219095 Vitis Species 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 235000019710 soybean protein Nutrition 0.000 claims description 2
- 235000021147 sweet food Nutrition 0.000 claims description 2
- 235000014620 theaflavin Nutrition 0.000 claims description 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims description 2
- 229940026509 theaflavin Drugs 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 54
- 235000012000 cholesterol Nutrition 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 7
- 235000015173 baked goods and baking mixes Nutrition 0.000 abstract description 2
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 abstract 1
- 235000015895 biscuits Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000014058 juice drink Nutrition 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 14
- 102000007330 LDL Lipoproteins Human genes 0.000 description 14
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 102000004895 Lipoproteins Human genes 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 241000207199 Citrus Species 0.000 description 5
- 240000000560 Citrus x paradisi Species 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 5
- 239000004410 anthocyanin Substances 0.000 description 5
- 229930002877 anthocyanin Natural products 0.000 description 5
- 150000004636 anthocyanins Chemical class 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- -1 fatty acid ester Chemical class 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 4
- 229920001991 Proanthocyanidin Polymers 0.000 description 4
- 244000291414 Vaccinium oxycoccus Species 0.000 description 4
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 108010046315 IDL Lipoproteins Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000010732 athyreosis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000007946 flavonol Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000001412 Mediterranean diet Nutrition 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 241000245026 Scoliopus bigelovii Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- KBFXONBVEJPQLK-UHFFFAOYSA-N benzoylsulfamic acid Chemical compound OS(=O)(=O)NC(=O)C1=CC=CC=C1 KBFXONBVEJPQLK-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960002577 colestipol hydrochloride Drugs 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 229960001767 dextrothyroxine Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- PLQIOFZPHAZJAM-UHFFFAOYSA-N oxo(phenyl)methanesulfonamide Chemical compound NS(=O)(=O)C(=O)C1=CC=CC=C1 PLQIOFZPHAZJAM-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229930182496 polymethoxyflavone Natural products 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000003036 tocotrienol group Chemical group 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C15/00—Butter; Butter preparations; Making thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明的某些具体实施方案中公开了一种含有包含类黄酮和生育三烯酚的活性物质组合的功能性食品。类黄酮可以包含柚皮素、橙皮素、川陈皮素或红橘素。生育三烯酚可以包含α-生育三烯酚、γ-生育三烯酚或δ-生育三烯酚。所述制剂可以通过如降低总胆固醇、三酰基甘油、LDL胆固醇或Apo B用于治疗心血管疾病。它们可以为可咀嚼或可食用的棒状食品、甜食、果汁饮料、酱状物、焙烤或仿焙烤的商品、饼干或口香糖的形式。
Description
相关申请
本申请要求于2004年5月26日提交的美国临时申请No.60/574,655的优先权,其并入此处作为参考。
背景技术
高脂血是哺乳动物的一种存在浓度异常高的血清循环脂质的病理状态。循环中脂质库组分主要是由甘油三酯(脂肪酸甘油酯)、胆固醇、和胆固醇的脂肪酸酯组成。据发现,这种分子通常都以用作转运机制的复合物的形式与特定的蛋白结合。高脂血是通常与哺乳动物血清中胆固醇、磷脂、和/或甘油三酯水平升高相关的疾病。
高脂血包括六种可遗传的高脂蛋白血症;这些类型通常称作脂蛋白表型。大多数血浆脂质,包括胆固醇和甘油三酯,不能游离地在血浆溶液中循环,而是与蛋白结合,并且作为被称作脂蛋白的大分子复合物被转运。根据表型对遗传性高脂蛋白血症进行分类很重要,因为饮食控制和药物治疗在很大程度上依赖于此信息。(The Merck Manual,16th edition,Robert Berkow and Andrew J.Fletcher,Merck & Co.,Inc.,Rahway,NJ.1992)。在当前治疗高脂血的实践中,目的是通过体重控制和饮食控制来降低脂质水平。作为饮食控制和体重控制的辅助物,还可以给药降血脂剂包括如处方药。
血浆脂蛋白是将脂质从合成部位和吸收部位运送到贮存和/或利用部位的载体。脂蛋白是内核具有甘油三酯和胆固醇酯,并且表面具有一层磷脂、非酯化的胆固醇和载脂蛋白的球状颗粒。根据水合密度(hydrateddensity),将脂蛋白分为五大类,称作乳糜微粒的非常大的富含甘油三酯的颗粒、极低密度脂蛋白(VLDL)、中密度脂蛋白(IDL)、低密度脂蛋白(LDL)以及高密度脂蛋白(HDL)。
载脂蛋白是脂蛋白中的蛋白成分,其具有三种主要功能:(1)保持脂蛋白颗粒的稳定性,(2)充当作用于脂蛋白的酶的辅因子,以及(3)通过受体介导的机制从循环中清除脂蛋白。四组载脂蛋白为:载脂蛋白A(Apo A)、B(Apo B)、C(Apo C)、以及E(Apo E)。
LDL是由含胆固醇酯和甘油三酯的疏水性脂质内核组成。LDL颗粒的脂质内核被含有磷脂、非酯化的胆固醇和Apo B的两性外壳包围。
若干研究表明,血液中Apo B水平升高是冠状动脉粥样硬化的可靠的标志(Sniderman,A.等.,Proc.Natl.Acad.Sci.USA,77:604-608(1980);Kwiterovich,P.O.等.,Am.J.Cardiol.,71:631-639(1993);McGiIl等.Coron.Artery Dis.,4:261-270(1993);Tomvall,P.等.,Circulation,88:2180-2189(1993))。
在美国,动脉粥样硬化并发症占所有死者的大约一半,并且占年龄在35岁到65岁之间的死者的约三分之一。动脉粥样硬化,或大动脉及中等大小的动脉中粥样斑块的形成是动脉硬化最常见的形式。与潜在的原始病理变化无关,例如年龄、血浆胆固醇水平升高、高动脉血压、吸烟、高密度脂蛋白(HDL)胆固醇水平降低、或过早的冠心病家族史的许多因素都与动脉粥样硬化的加速有关。
冠心病导致死亡的风险与大于180mg/dl的血清总胆固醇水平具有持续并分级的(graded)关系(Stamler,J.等.,(1986)JAMA 256:2823)。在美国约三分之一的成年人的水平超过了240mg/dl,因此,患冠心病的风险是胆固醇水平低于180mg/dl的人的两倍。动脉粥样硬化的加速主要和LDL的升高相关,或β片段(βfraction),与动脉粥样硬化成负相关(Castelli,W.P.等.(1986)JAMA 256:2835)。HDL发挥保护作用,并且总胆固醇与HDL胆固醇的比例比各自单独的水平能够更好地预示冠心病。总胆固醇水平被分为适宜(<200mg/dl),临界高(borderline high,200-239mg/dl),或高(>240mg/dl)(Report of the National EducationProgram Expert Panel on Detection,Evaluation,and Treatment of HighBlood Cholesterol in Adults(1988)Arch Intern Med 148:36)。
胆固醇代谢和冠心病的研究进展开创了更加强调预防性治疗的时代。检测和治疗成年人高血液胆固醇的新指导方针建议胆固醇水平高的患者或临界高水平并伴有两种或更多种其他危险因素的患者应该测定LDL。LDL胆固醇水平又被分为临界高危(130-159mg/dl)或高危(>160mg/dl)。对于那些LDL处于高危水平的患者以及那些具有两种或者更多种其他危险因素的处于临界高危水平的患者而言,推荐采用饮食疗法。LDL水平高于189mg/dl的所有患者以及具有两种或者更多种其他危险因素的LDL胆固醇水平在159到189mg/dl之间的患者推荐采用药物疗法。
考虑到上述情况,发现大量化合物已被建议用于治疗哺乳动物高脂血就不足为奇了。例如,盐酸考来替泊(美国专利No.3,692,895和3,803,237)是一种碱性阴离子交换树脂,其在摄入以后,与肠中的胆酸多价鳌合(sequester)。这样就促进了胆酸的产生,从而利用并消耗了体内贮存的胆固醇。从而又降低了LDL水平。美国专利No.3,674,836中所述的吉非贝齐也用于这种治疗。也以约1.5到6g/天的剂量口服给药烟酸(3-吡啶羧酸)用于治疗高胆固醇血症。其它偶尔用于治疗高脂血的药物包括新霉素、醋酸炔诺酮、氧雄龙、右旋甲状腺素(Remington′sPharmaceutical Sciences,(第17版.,Mack Pub.Co.,1985),pp.863-865)。美国专利No.4,499,303记载了使用一类N-苯甲酰基氨基磺酸盐和苯甲酰基磺酰胺用作有效的降血脂药物。美国专利No.4,395,417提出使用环亚胺、二酮类、还原的二酮类及类似物作为有效的药物。
本发明涉及采用类黄酮和生育三烯酚的组合预防和治疗心血管疾病(如高胆固醇血症和动脉粥样硬化)的组合物和方法。类黄酮是主要(unbiquitiously)存在于植物性食品尤其是橙、葡萄柚、和柑橘中的多酚类化合物。生育三烯酚存在于棕榈油中并且是具有不饱和侧链的一种形式的维生素E。在预防和/或治疗动脉粥样硬化和/或高胆固醇血症的实践中,类黄酮和生育三烯酚用于抑制胆固醇、低密度脂蛋白(LDL)及Apo B蛋白的生成。含有柑橘类类黄酮和生育三烯酚的组合物用于预防和/或抑制血清总胆固醇、LDL及Apo B的生成。
类黄酮
流行病学研究显示,存在于地中海式饮食(Mediterranean diet)中的类黄酮可以减少冠心病的死亡风险(Hertog,M.G.等,1993,Lancet:342,1007-1011)。大豆异黄酮,例如作为大豆蛋白制品中的微量成分的染料木黄酮具有降低胆固醇的作用(Kurowska,E.M.等,1990,J.Nutr.120:831-836)。存在于柑橘类果汁如橙汁和葡萄柚汁中的类黄酮分别包括但不限于橙皮素(hesperetin)和柚皮素(naringenin)。柑橘中存在的类黄酮包括但不限于红橘素或川陈皮素。
生育三烯酚存在于棕榈油中并且是具有不饱和侧链的一种形式的维生素E。它们包括但不限于α-生育三烯酚、γ-生育三烯酚或δ-生育三烯酚。
本领域仍需要用于预防及治疗心血管疾病的包括类黄酮和生育三烯酚的化合物。
本申请通篇提及了许多专利和出版物。这些出版物和专利中所公开的内容全部并入本申请作为参考。
发明内容
本发明的目的是提供一种含有类黄酮和生育三烯酚的用于治疗和/或预防心血管疾病的功能性食品。
本发明的另一个目的是提供通过给药含有类黄酮和生育三烯酚的功能性食品来治疗心血管疾病的方法。
本发明的另一个目的是提供利用类黄酮和生育三烯酚来降低总胆固醇从而治疗动脉粥样硬化或高胆固醇血症的功能性食品和方法。
本发明的另一个目的是提供利用类黄酮和生育三烯酚来降低三酰基甘油从而治疗动脉粥样硬化或高胆固醇血症的功能性食品和方法。
本发明的另一个目的是提供利用类黄酮和生育三烯酚来降低LDL胆固醇从而治疗动脉粥样硬化或高胆固醇血症的功能性食品和方法。
本发明的另一个目的是提供利用类黄酮和生育三烯酚来降低Apo B从而治疗动脉粥样硬化或高胆固醇血症的功能性食品和方法。
本发明的另一个目的是提供利用类黄酮和生育三烯酚来治疗动脉粥样硬化或高胆固醇血症的功能性食品和方法,其中该功能性食品具有低水平的脱氧肾上腺素。
本发明某些上述目的可以通过本发明来实现,其中在某些具体实施方案中涉及包含含有多甲氧基化的类黄酮和生育三烯酚的活性物质组合的功能性食品。
在某些具体实施方案中,本发明涉及包含含有约75∶25到约95比例的类黄酮和生育三烯酚的活性物质组合的功能性食品。
在某些具体实施方案中,本发明涉及包含含有类黄酮和生育三烯酚的活性物质组合的功能性食品,该功能性食品给药后使总胆固醇降低至少10%。
在某些具体实施方案中,本发明涉及含有类黄酮和生育三烯酚的功能性食品,该功能性食品给药后使三酰基甘油降低至少15%。
在某些具体实施方案中,本发明涉及含有类黄酮和生育三烯酚的功能性食品,该功能性食品给药后使LDL胆固醇降低至少10%。
在某些具体实施方案中,本发明涉及包含含有类黄酮和生育三烯酚的活性物质组合的功能性食品,该功能性食品给药后使Apo B降低至少10%。
在某些具体实施方案中,本发明涉及通过给药本文所公开的功能性食品来治疗心血管疾病的方法。
术语“精油”是指果汁蒸发之后残留的油溶性成分(如,级分(fraction))。
术语“果皮油”是指从柑橘类水果(citrus fruit)的果皮中分离得到的油。
术语“果皮”是指柑橘类水果的果皮,为了本发明目的,它可以经过例如干燥、切碎或粒化。
术语“柑橘类水果”是指来自柑橘属的水果,包括橙、柠檬、甜柠檬(lime)、柑橘、葡萄柚(如粉红葡萄柚(pink grapefruit)、红皮柚(redpeel grapefruit))以及特别是酸橙(Citrus aurantium)。
术语“改质化的水果”是指已经被榨取果汁的水果。改质化的水果可以为如浆状物或压榨饼的形式。术语“Tomah压榨饼”是指美国专利No.5,320,861和5,320,861中记载的特别优选的压榨饼,它比通过常规方法制备的压榨饼含有更高水平的所需的植物化学成分。具体而言,“Tomah压榨饼”形式的改质化的蔓越橘果实比通过常规方法制备的压榨饼含有更高水平的花色素苷(anthocyanin)、酚酸和原花色素(proanthocyanidin)。例如,花色素苷含量通常占原产蔓越橘果实中含量的30%或更高,酚酸含量通常占原产蔓越橘果实的8%或更高,而原花色素含量通常占原产蔓越橘果实的60%或更高。
术语“分离”是指从其天然环境中去除或改变组分或化合物。
术语“类黄酮”包括但不限于多甲氧基化的类黄酮,是指本发明的衍生物中存在的芳香性、含氧、杂环的色素的组中的任何成员,而且包括例如以下化学亚组中的成员:1)儿茶素,2)白花色素和黄烷酮,3)fiavanin、黄酮、和花色素苷,以及4)黄酮醇。在优选的具体实施方案中,类黄酮包括如原花色素、黄烷-3-醇、花色素苷、或黄烷醇。类黄酮可以包括如柚皮素、橙皮素、川陈皮素、和/或红橘素。
术语“生育三烯酚”是指以可检测水平存在于本发明水果衍生物中的任何生育酚(T)或生育三烯酚(T3)化合物,例如,α-生育酚、γ-生育酚、δ-生育酚、α-生育三烯酚、γ-生育三烯酚、δ-生育三烯酚、或其组合。
出于本发明的目的,术语“功能性食品”是用本文公开的类黄酮和生育三烯酚增强或强化的任何可食用的或可饮用的食品或饮食成分(例如果汁、焙烤食品、苹果酱等)。该功能性食品可以是如固体、液体、半固体、或其组合。术语“功能性食品”还涵盖可食用和可饮用的营养补充剂。
具体实施方式
在某些具体实施方案中,本发明涉及包含含有多甲氧基化的类黄酮和生育三烯酚的活性物质组合的功能性食品。
在某些具体实施方案中,该功能性食品是可食用或可饮用的组合物的形式,例如食品如可咀嚼的或可食用的棒状食品(chewable or ediblebars)、甜食(如巧克力棒)、曲奇、果汁饮料、焙烤或仿焙烤的商品(如布朗尼(brownies))、饼干、锭剂、或口香糖。优选的可咀嚼或可饮用的棒状食品(bar)包括巧克力棒和布朗尼。这种食品因提供了如上所述的类黄酮和生育三烯酚的好处并且还提供了缓解饥饿或疲劳的好处从而是有益的。这种功能性食品对参与运动或其他形式的锻炼的人特别有益。
该功能性食品还可为如黄油、人造黄油、面包、蛋糕、奶昔冰淇淋(milk shakes)、冰淇淋、酸奶酪和其他发酵的牛奶产品的形式。
该功能性食品还可以为用于撒在肉类、色拉或其它食物上的粉末的形式。它们可以并入固体食物如块状糖(candy bars)、谷类、健康棒状食品(health bar)和其他食物中。
其他形式的功能性食品可以是早餐谷类如谷片(grain flake)或穆兹利(muesli)。
在某些具体实施方案中,本发明涉及包含药物成分的功能性食品,该药物成分包含含有多甲氧基化的类黄酮和生育三烯酚的活性物质组合,该药物成分选自以下组中:从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果、以及其组合。
在某些具体实施方案中,该活性物质组合含有约75∶25比例到约95∶5比例、约90∶10比例、约80∶20比例或约95∶5比例的类黄酮和生育三烯酚。
在某些具体实施方案中,本发明的功能性食品的药物成分含有约50%到约90%的类黄酮和生育三烯酚、约60%到约80%的该活性物质组合、或约70%的该活性物质组合。
本发明的类黄酮可以是多甲氧基化的类黄酮。在某些具体实施方案中,该类黄酮包含选自以下组中的成员:柚皮素、橙皮素、川陈皮素、红橘素及其组合。
本发明的生育三烯酚可以例如选自以下组中:α-生育三烯酚、γ-生育三烯酚、δ-生育三烯酚及其组合。
在某些具体实施方案中,本发明的功能性食品的活性组合来源于选自以下组中的成员:从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果、以及其组合。
在某些具体实施方案中,本发明的功能性食品含有治疗具有患心血管疾病的风险或患有心血管疾病如高胆固醇血症或动脉粥样硬化的人类对象有效的量的类黄酮和生育三烯酚。
在某些具体实施方案中,本发明的功能性食品每份包含约60mg的生育三烯酚和约560mg的类黄酮;每份约10mg到约80mg的生育三烯酚和约150mg到约750mg的类黄酮;或者每份约30mg的生育三烯酚和约270mg的类黄酮。
在本发明的方法中,活性物质的每日剂量可以是如约60mg的生育三烯酚和约560mg的类黄酮、约10mg到约80mg的生育三烯酚和约150mg到约750mg的类黄酮、或约30mg的生育三烯酚和约270mg的类黄酮。
在本发明的方法中,类黄酮和生育三烯酚可以相同的功能性食品或不同的功能性食品给药。
在某些具体实施方案中,该功能性食品含有低于约1%的脱氧肾上腺素、低于约0.5%的脱氧肾上腺素、或低于0.1%的脱氧肾上腺素。
在某些具体实施方案中,该功能性食品的药物成分含有低于约1%的脱氧肾上腺素、低于约0.5%的脱氧肾上腺素、或低于0.1%的脱氧肾上腺素。
在某些具体实施方案中,本发明的功能性食品使总胆固醇降低至少10%、20%或30%。
在某些具体实施方案中,本发明的功能性食品在单个患者或患者群中、在单剂量给药、多剂量给药(如四星期后)或稳态给药后使总胆固醇降低至少10%、20%或30%。
在某些具体实施方案中,本发明的功能性食品使三酰基甘油降低至少15%、25%或35%。
在某些具体实施方案中,本发明的功能性食品在单个患者或患者群中、在单剂量给药、多剂量给药(如四星期后)或稳态给药后使三酰基甘油降低至少15%、25%或35%。
在某些具体实施方案中,本发明的功能性食品使LDL胆固醇降低至少10%、20%或30%。
在某些具体实施方案中,本发明的功能性食品在单个患者或患者群中、在单剂量给药、多剂量给药(如四星期后)或稳态给药后使LDL胆固醇降低至少10%、20%或30%。
在某些具体实施方案中,本发明的功能性食品使Apo B降低至少10%、20%或30%。
在某些具体实施方案中,本发明的功能性食品在单个患者或患者群中、在单剂量给药、多剂量给药(如四星期后)或稳态给药后使总胆固醇降低至少10%、20%或30%。
在某些具体实施方案中,本发明的功能性食品包含含有类黄酮和生育三烯酚及选自以下组中的另外的活性物质的活性物质组合:大豆蛋白、大豆异黄酮、葡萄籽提取物、松树皮提取物、补骨脂(gugulipids)、甘蔗原素(Policosinols)、pantesine、烟酸、α硫辛酸、茶黄素(tea flavins)、辅酶q 10、叶黄素(lutein)、他汀类(statins)及其组合。
在某些具体实施方案中,他汀类药物选自以下组中:普伐他汀、辛伐他汀、洛伐他汀、阿托伐他汀、氟伐他汀、西立伐他汀及其组合。
实施例
实施例1
研究了黄酮和生育三烯酚的组合对降低人类对象的胆固醇的作用。
研究设计:
对十名血清总胆固醇>5.9mmol/L、LDL胆固醇4.0mmol/L且血清三酰基甘油<3.5mmol/L(分别>230mg/dl、>155mg/dl以及<307mg/dl)的高胆固醇血症对象每天给予由270mg多甲氧基黄酮和30mg生育三烯酚组成的补充剂四周。参与本研究的对象必须无甲状腺失调、肾脏失调和糖尿病。同时,要求服用降胆固醇药物的对象在研究之前四周停止该治疗。
为了确定该治疗是否改善了与心脏病的高风险有关的参数,在研究开始时以及4周结束时抽取禁食血样用于分析血浆总胆固醇和脂蛋白胆固醇、血浆载脂蛋白B(与LDL有关)和A1(与HDL有关)、总三酰基甘油。该草案获得西安大略大学(University of Western Ontario)人类伦理委员会(Human Ethics Committee)的批准并且从各对象处获得知情同意。
通过使用CHOL试剂或三酰基甘油GPO试剂用酶定时终点法(enzymatic timed-endpoint)测定胆固醇和三酰基甘油。Apo B和Apo A1的血浆浓度使用BNII系统进行immunoephelometrically分析。
指示对象在研究期间维持热量摄取。在治疗之前和之后通过测量体重指数(Body Mass Index,BMI)对其进行测定。
利用重复测量方差分析(ANOVA)之后通过Dunnet氏t检验来分析四周之后相对基线的变化。
结果:
使用90%类黄酮和10%生育三烯酚的组合治疗与许多有利的效果有关。与这种组合相关的治疗与总胆固醇、LDL胆固醇和血清三酰基甘油的显著降低有关。参见表1。结果显示类黄酮和生育三烯酚的组合使人的胆固醇降低。
表1
变量 0周 第4周
体重指数(kg/m2) | 28.84.6 | 28.28.64.5 |
总胆固醇(mg/dl) | 266.8234.80 | 201.0827.07 |
VLDL胆固醇(mg/dl) | 30.9411.6 | 34.8015.47 |
LDL胆固醇(mg/dl) | 181.7530.94 | 146.9527.07 |
HDL胆固醇(mg/dl) | 42.5411.60 | 42.5411.60 |
实施例2
临床试验2:多甲氧基化的黄酮和生育三烯酚的组合的降低人类对象的胆固醇的性质
该项研究的目的是评价黄酮和生育三烯酚的组合在人类对象中的心脏保护能力。
研究设计:
对十名高胆固醇血症对象每天给予由270mg多甲氧基化的黄酮和30mg生育三烯酚组成的补充剂四周。参与本研究的对象必须无甲状腺失调、肾脏失调及糖尿病。同时,要求服用降胆固醇药物的对象在研究之前四周停止该治疗。
在开始之前(基线)及4周期间结束时从前臂静脉取血样。使用标准方法分析血脂谱(plasm lipids profile)及其他代谢参数。使用常规的水银压力计通过计算两次读数的平均值来记录坐姿血压。
结果:
使用90%类黄酮和10%生育三烯酚的组合治疗与许多有利的效果有关。与这种组合相关的治疗与总胆固醇(19.7%)、LDL胆固醇(22.01%)、血清三酰基甘油(28.4%)、Apo B(20.9%)及心脏收缩压的降低有关。参见表2。该结果显示类黄酮和生育三烯酚的组合对患有中度高胆固醇血症的对象具有心脏保护能力。
表2
变量 | 0周 | 第4周 |
心脏收缩压mmHg | 123.022.4 | 116.012.7 |
心脏舒张压mmHg | 79.013.0 | 76.09.2 |
体重,kg | 80.810.9 | 81.111.7 |
体重指数(BMI),kg/m2 | 27.41.8 | 27.51.9 |
总胆固醇,mmol/L | 255.6135.96 | 205.3418.95 |
三酰基甘油,mmol/L | 77.3429.78 | 55.4113.64 |
HDL胆固醇,mmol/L | 42.929.67 | 44.088.51 |
LDL胆固醇,mmol/L | 197.6034.03 | 154.2916.63 |
实施例3
选自从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果及其组合的含有多甲氧基化的类黄酮和生育三烯酚的成分可以并入一种或多种下列食品以制备功能性食品。
a)布朗尼
b)奶昔冰淇淋
c)果汁
d)苹果酱
e)能量棒(energy bar)
f)运动饮料
g)巧克力棒
h)早餐谷类
i)酸奶酪
j)人造黄油
Claims (68)
1、一种包含可食用的固体或液体以及含有多甲氧基化的类黄酮和生育三烯酚的活性物质组合的功能性食品。
2、如权利要求1的功能性食品,其中所述活性物质组合包含约75∶25到约95∶5比例的类黄酮和生育三烯酚。
3、如权利要求1的功能性食品,其中所述活性物质组合包含约90∶10比例的类黄酮和生育三烯酚。
4、如权利要求1的药物成分,其中所述活性物质组合包含约80∶20比例的类黄酮和生育三烯酚。
5、如权利要求1的功能性食品,其中所述类黄酮包括选自以下组中的成员:柚皮素、橙皮素、川陈皮素、以及红橘素。
6、如权利要求1的功能性食品,其中所述生育三烯酚选自以下组中:α-生育三烯酚、γ-生育三烯酚、以及δ-生育三烯酚。
7、如权利要求1的功能性食品,其中所述活性物质组合来源于选自以下组中的成员:从柑橘类水果中分离得到的精油、从柑橘类水果中分离得到的果皮油、从柑橘类水果中分离得到的果皮、改质化的柑橘类水果、以及其组合。
8、如权利要求1的功能性食品,其中所述组合是以治疗具有患心血管疾病的风险或患有心血管疾病的人类对象有效的量存在。
9、如权利要求10的功能性食品,其中所述心血管疾病是高胆固醇血症或动脉粥样硬化。
10、如权利要求1的功能性食品,其为可咀嚼的或可食用的棒状食品、甜食、曲奇、果汁饮料、酱状物(puree)、焙烤或仿焙烤的商品、饼干、锭剂、或口香糖的形式。
11、如权利要求1的功能性食品,其为布朗尼或巧克力棒的形式。
12、如权利要求1的功能性食品,其为黄油、人造黄油、面包、蛋糕、奶昔冰淇淋、冰淇淋、酸奶酪和其他发酵的牛奶产品的形式。
13、如权利要求1的功能性食品,其为粉末或谷类的形式。
14、如权利要求1的功能性食品,其每份包含约10mg到约80mg的生育三烯酚和约150mg到约750mg的类黄酮。
15、如权利要求1的功能性食品,其每份包含约30mg的生育三烯酚和约270mg的类黄酮。
16、如权利要求1的功能性食品,其每份包含约60mg的生育三烯酚和约560mg的类黄酮。
17、如权利要求1的功能性食品,其中所述功能性食品使总胆固醇降低至少10%。
18、如权利要求17的功能性食品,其中所述功能性食品在单个患者中使总胆固醇降低至少10%。
19、如权利要求17的功能性食品,其中所述功能性食品在患者群中使总胆固醇降低至少10%。
20、如权利要求17-19任意一项的功能性食品,其中所述功能性食品在单剂量给药后使总胆固醇降低至少10%。
21、如权利要求17-19任意一项的功能性食品,其中所述功能性食品在多剂量给药后使总胆固醇降低至少10%。
22、如权利要求17-19任意一项的功能性食品,其中所述功能性食品在稳态给药后使总胆固醇降低至少10%。
23、如权利要求21的功能性食品,其中所述功能性食品在给药4周后使总胆固醇降低至少10%。
24、如权利要求17-23任意一项的功能性食品,其中所述功能性食品使总胆固醇降低至少20%。
25、如权利要求17-23任意一项的功能性食品,其中所述功能性食品使总胆固醇降低至少30%。
26、如权利要求1的功能性食品,其中所述功能性食品使三酰基甘油降低至少15%。
27、如权利要求26的功能性食品,其中所述功能性食品在单个患者中使三酰基甘油降低至少15%。
28、如权利要求26的功能性食品,其中所述功能性食品在患者群中使三酰基甘油降低至少15%。
29、如权利要求26-28任意一项的功能性食品,其中所述功能性食品在单剂量给药后使三酰基甘油降低至少15%。
30、如权利要求26-28任意一项的功能性食品,其中所述功能性食品在多剂量给药后使三酰基甘油降低至少15%。
31、如权利要求26-28任意一项的功能性食品,其中所述功能性食品在稳态给药后使三酰基甘油降低至少15%。
32、如权利要求30的功能性食品,其中所述功能性食品在给药4周后使三酰基甘油降低至少15%。
33、如权利要求26-32任意一项的功能性食品,其中所述功能性食品使三酰基甘油降低至少25%。
34、如权利要求26-32任意一项的功能性食品,其中所述功能性食品使三酰基甘油降低至少35%。
35、如权利要求1的功能性食品,其中所述功能性食品使LDL胆固醇降低至少10%。
36、如权利要求35的功能性食品,其中所述功能性食品在单个患者中使LDL胆固醇降低至少10%。
37、如权利要求35的功能性食品,其中所述功能性食品在患者群中使LDL胆固醇降低至少10%。
38、如权利要求35-37任意一项的功能性食品,其中所述功能性食品在单剂量给药后使LDL胆固醇降低至少10%。
39、如权利要求35-37任意一项的功能性食品,其中所述功能性食品在多剂量给药后使LDL胆固醇降低至少10%。
40、如权利要求35-37任意一项的功能性食品,其中所述功能性食品在稳态给药后使LDL胆固醇降低至少10%。
41、如权利要求39的功能性食品,其中所述功能性食品在给药4周后使LDL胆固醇降低至少10%。
42、如权利要求35-41任意一项的功能性食品,其中所述功能性食品使LDL胆固醇降低至少20%。
43、如权利要求35-41任意一项的功能性食品,其中所述功能性食品使LDL胆固醇降低至少30%。
44、如权利要求1的功能性食品,其中所述功能性食品使Apo B降低至少10%。
45、如权利要求44的功能性食品,其中所述功能性食品在单个患者中使Apo B降低至少10%。
46、如权利要求44的功能性食品,其中所述功能性食品在患者群中使Apo B降低至少10%。
47、如权利要求44-46任意一项的功能性食品,其中所述功能性食品在单剂量给药后使Apo B降低至少10%。
48、如权利要求44-46任意一项的功能性食品,其中所述功能性食品在多剂量给药后使Apo B降低至少10%。
49、如权利要求44-46任意一项的功能性食品,其中所述功能性食品在稳态给药后使Apo B降低至少10%。
50、如权利要求44的功能性食品,其中所述功能性食品在给药4周后使Apo B降低至少10%。
51、如权利要求44-50任意一项的功能性食品,其中所述功能性食品使Apo B降低至少20%。
52、如权利要求44-50任意一项的功能性食品,其中所述功能性食品使Apo B降低至少30%。
53、如权利要求1的功能性食品,其还包含选自以下组中的另外的活性物质:大豆蛋白、大豆异黄酮、葡萄籽提取物、松树皮提取物、补骨脂、甘蔗原素、pantesine、烟酸、α硫辛酸、茶黄素、辅酶q 10、叶黄素、他汀类及其组合。
54、一种治疗具有患心血管疾病的风险或患有心血管疾病的人类对象的方法,其包括给药有效量的如权利要求1-53中任意一项的功能性食品。
55、如权利要求54的方法,其中所述心血管疾病是高胆固醇血症或动脉粥样硬化。
56、一种降低患者的总胆固醇的方法,其包括对有此需要的患者给药权利要求17-25的功能性食品。
57、一种降低患者的三酰基甘油的方法,其包括对有此需要的患者给药权利要求26-34的功能性食品。
58、一种降低患者的LDL胆固醇的方法,其包括对有此需要的患者给药权利要求35-43的功能性食品。
59、一种降低患者的Apo B的方法,其包括对有此需要的患者给药权利要求44-52的功能性食品。
60、如权利要求54-59的方法,其中所述组合是以约10mg/天到约80mg/天生育三烯酚和约150mg/天到约750mg/天类黄酮的每日剂量给药。
61、如权利要求54-59的方法,其中所述组合是以约30mg/天生育三烯酚和约270mg/天类黄酮的每日剂量给药。
62、如权利要求54-59的方法,其中所述组合是以约60mg/天生育三烯酚和约560mg/天类黄酮的每日剂量给药。
63、如权利要求56-59的方法,其中所述给药是单剂量给药。
64、如权利要求56-59的方法,其中所述给药是多剂量给药。
65、如权利要求56-59的方法,其中所述给药达到稳态。
66、如权利要求64的方法,其中所述给药维持至少4周。
67、如权利要求7的功能性食品,其中所述柑橘类水果是酸橙。
68、前述权利要求中任意一项的功能性食品,其含有低于约1%的脱氧肾上腺素、低于约0.5%的脱氧肾上腺素、或低于0.1%的脱氧肾上腺素。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57465504P | 2004-05-26 | 2004-05-26 | |
US60/574,655 | 2004-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1988902A true CN1988902A (zh) | 2007-06-27 |
Family
ID=35450643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800254064A Pending CN1988902A (zh) | 2004-05-26 | 2005-05-24 | 含有类黄酮和生育三烯酚的功能性食品及其方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20060013861A1 (zh) |
EP (1) | EP1748773A4 (zh) |
KR (1) | KR20070088324A (zh) |
CN (1) | CN1988902A (zh) |
AU (1) | AU2005247160A1 (zh) |
CA (1) | CA2567963A1 (zh) |
IL (1) | IL179474A0 (zh) |
WO (1) | WO2005115377A1 (zh) |
ZA (1) | ZA200610167B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579356B2 (en) * | 2006-01-25 | 2017-02-28 | Reliv International Inc. | Dietary supplements for reducing cholesterol levels |
JP2008247826A (ja) * | 2007-03-30 | 2008-10-16 | Hiroshima Univ | 血糖値調整剤およびまたは血中コレステロール値調整剤 |
EP2183977A1 (en) * | 2008-11-06 | 2010-05-12 | Unilever N.V. | Food product |
US20100196549A1 (en) * | 2009-02-03 | 2010-08-05 | Tropicana Products, Inc. | Microencapsulated citrus phytochemicals and application to sports drinks |
US20110293753A1 (en) * | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
WO2014048968A1 (en) * | 2012-09-28 | 2014-04-03 | Unilever Plc | Frozen confection comprising valerenic acid and one or more flavones |
US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
EP3002335A1 (de) * | 2014-10-03 | 2016-04-06 | Symrise AG | Verfahren zur biotechnologischen Herstellung von Flavonoiden |
AU2016217912A1 (en) * | 2015-02-11 | 2017-09-28 | Bioactor Bv | Compounds and compositions for improving power output and oxygen efficiency |
CN107712869A (zh) * | 2017-09-01 | 2018-02-23 | 顾春华 | 一种控糖降三高减肥补充调理营养的食品 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055627A1 (en) * | 1997-09-26 | 2001-12-27 | Najla Guthrie | Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols |
US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
US6251400B1 (en) * | 1997-09-26 | 2001-06-26 | Kgk Synergize Inc | Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols |
KR20000019716A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 |
US6987125B1 (en) * | 1998-10-06 | 2006-01-17 | The United States Of America As Represented By The Secretary Of Agriculture | Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones |
CA2403548A1 (en) * | 2000-03-17 | 2001-09-27 | United States Department Of Agriculture | Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones |
EP1270004B1 (en) * | 2000-03-31 | 2010-06-09 | Eisai R&D Management Co., Ltd. | Use of gamma-tocotrienol as diuretic |
US20020054924A1 (en) * | 2000-04-13 | 2002-05-09 | Leahy Margaret M. | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor |
US20020090404A1 (en) * | 2000-09-15 | 2002-07-11 | Najla Guthrie | Components of canola for treating hyperlipidemia |
WO2002022145A2 (en) * | 2000-09-15 | 2002-03-21 | Kgk Synergize | Components of canola for the treatment of cancer |
GB0026018D0 (en) * | 2000-10-24 | 2000-12-13 | Novartis Nutrition Ag | New composition |
GB0028429D0 (en) * | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
WO2002055071A1 (en) * | 2001-01-15 | 2002-07-18 | Kgk Synergize | Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols |
AU2002308324B2 (en) * | 2001-05-02 | 2008-04-03 | Kgk Synergize Inc. | Polymethoxylated flavones for treating insulin resistance |
US7074825B2 (en) * | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
EP1415549A1 (en) * | 2002-11-01 | 2004-05-06 | Galileo Laboratories, Inc. | Synergistic antioxidant combination of tocols and polyphenols |
WO2005096704A2 (en) * | 2004-04-08 | 2005-10-20 | Kgk Synergize Inc. | Cholesterol lowering composition |
US20060013901A1 (en) * | 2004-05-26 | 2006-01-19 | Kgk Synergize Inc. | Compositions comprising flavonoids and tocotrienols and methods thereof |
WO2005115376A1 (en) * | 2004-05-26 | 2005-12-08 | Kgk Synergize Inc | Pharmaceutical products for treating neoplastic disease and inflammation |
-
2005
- 2005-05-24 AU AU2005247160A patent/AU2005247160A1/en not_active Abandoned
- 2005-05-24 CA CA002567963A patent/CA2567963A1/en not_active Abandoned
- 2005-05-24 WO PCT/IB2005/001424 patent/WO2005115377A1/en active Application Filing
- 2005-05-24 KR KR1020067027105A patent/KR20070088324A/ko not_active Application Discontinuation
- 2005-05-24 US US11/135,675 patent/US20060013861A1/en not_active Abandoned
- 2005-05-24 ZA ZA200610167A patent/ZA200610167B/en unknown
- 2005-05-24 CN CNA2005800254064A patent/CN1988902A/zh active Pending
- 2005-05-24 EP EP05743956A patent/EP1748773A4/en not_active Withdrawn
-
2006
- 2006-11-21 IL IL179474A patent/IL179474A0/en unknown
-
2008
- 2008-10-13 US US12/250,328 patent/US20090156663A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL179474A0 (en) | 2007-05-15 |
KR20070088324A (ko) | 2007-08-29 |
WO2005115377A1 (en) | 2005-12-08 |
US20060013861A1 (en) | 2006-01-19 |
US20090156663A1 (en) | 2009-06-18 |
AU2005247160A1 (en) | 2005-12-08 |
EP1748773A4 (en) | 2008-11-12 |
WO2005115377B1 (en) | 2006-02-16 |
CA2567963A1 (en) | 2005-12-08 |
EP1748773A1 (en) | 2007-02-07 |
ZA200610167B (en) | 2008-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1988902A (zh) | 含有类黄酮和生育三烯酚的功能性食品及其方法 | |
US6054128A (en) | Dietary supplements for the cardiovascular system | |
Egert et al. | Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules | |
M Patti et al. | Nutraceuticals as an important part of combination therapy in dyslipidaemia | |
AU2005247159B2 (en) | Pharmaceutical products for treating neoplastic disease and inflammation | |
US20050101660A1 (en) | Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease | |
MX2007009817A (es) | Usos terapeuticos de extractos de tomate. | |
CN101001624A (zh) | 含有类黄酮和生育三烯酚的组合物及其方法 | |
de Santana et al. | Association between soy and green tea (Camellia sinensis) diminishes hypercholesterolemia and increases total plasma antioxidant potential in dyslipidemic subjects | |
US20070104730A1 (en) | Methods and compositions employing pomegranate extracts and fementation products of statin-producing fungi | |
JP2008513349A (ja) | フラボノイドとトコトリエノールを含む機能性食品及びその方法 | |
WO2005082390A1 (ja) | 脂肪蓄積抑制剤 | |
US20060160753A1 (en) | Micronutrient formulation for cognitive & mood benefits | |
EP1729598B1 (en) | Composition; use of a composition and a method for preventing fat absorption | |
Keller | Supplemental and complementary alternatives to hormone replacement therapy | |
Basile et al. | Daily intake of pasteurized orange juice decreases serum cholesterol, fasting glucose and diastolic blood pressure in adults | |
Jacob | Evidence that diet modification reduces in vivo oxidant damage | |
Lim et al. | The effects of functional tea (Mori Folium, Lycii Fructus, Chrysanthemi Flos, Zizyphi Fructus, Sesamum Semen, Raphani Semen) supplement with medical nutrition therapy on the blood lipid levels and antioxidant status in subjects with hyperlipidemia | |
EP1673988A1 (en) | Micronutrient formulation for cognitive & mood benefits | |
AU2013205996A1 (en) | Functional foods comprising flavonoids and tocotrienols and methods thereof | |
Acuff | Vitamin E: Bioavailability and function of natural and synthetic forms | |
Olivo | Getting to the heart of the matter: nutraceuticals supporting cardiovascular health help address a growing health crisis | |
Ashwell | The Influence of Dietary Factors on Different Physiological Risk Factors: See the outer ring of the Round Table in the colour section | |
Ho | THE EFFECTS OF RED WINE AND GRAPE JUICE CONSUMPTION IN OVERWEIGHT INDIVIDUALS ON MULTIPLE HEALTH PARAMETERS | |
KR20000023557A (ko) | 헤스페리딘 또는 헤스페레틴을 포함하는 아실 코에이:콜레스테롤-오-아실트랜스퍼레이즈 저해제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070627 |